Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 518
- Registration Number
- NCT05922345
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
🇨🇳TianJin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT05913089
- Locations
- 🇨🇳
Weifang People's Hospital, Weifang, Shandong, China
🇨🇳Beijing Chaoyang Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, Beijing, China
TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 92
- Registration Number
- NCT05894421
- Locations
- 🇨🇳
The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 480
- Registration Number
- NCT05862337
- Locations
- 🇨🇳
The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Ganzhou People's Hospital, Ganzhou, Jiangxi, China
🇨🇳Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China
To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer.
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT05859373
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT05849727
- Locations
- 🇨🇳
Bozhou People's Hospital, Bozhou, Anhui, China
🇨🇳Peking University Shougang Hospital, Beijing, Beijing, China
🇨🇳The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 75
- Registration Number
- NCT05834543
- Locations
- 🇨🇳
Tongling People's Hospital, Tongling, Anhui, China
🇨🇳The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳AnYang Tumor Hospital, Anyang, Henan, China
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT05830500
- Locations
- 🇨🇳
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China
🇨🇳Gansu Cancer Hospital, Lanzhou, Gansu, China
🇨🇳Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05815862
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳Shanghai Pulmonary Hospital, Shanghai, China
A Bioequivalence Study of Sunitinib Malate Capsules.
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05800106
- Locations
- 🇨🇳
Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China